MDPI Journal Calls for Papers onHistone Deacetylasesin Disease Research

MDPI's open-access journal Pharmaceuticals announces a thematic issue on histone deacetylases (HDACs) and their applications in cancer, neurodegenerative, and inflammatory diseases. Researchers are invited to submit original research articles, reviews, and short communications exploring HDACs' role in these diseases.

author-image
Bijay Laxmi
New Update
MDPI Journal Calls for Papers onHistone Deacetylasesin Disease Research

MDPI Journal Calls for Papers onHistone Deacetylasesin Disease Research

MDPI's open-access journal Pharmaceuticals has announced a thematic issue focused on histone deacetylases (HDACs) and their applications in cancer, neurodegenerative, and inflammatory diseases. The journal is inviting researchers to submit original research articles, reviews, and short communications that explore the role of HDACs in these diseases and their potential as therapeutic targets.

Why this matters: Understanding the role of HDACs in disease development and progression can lead to the discovery of new therapeutic strategies for cancer, neurodegenerative, and inflammatory diseases, ultimately improving human health and quality of life. Furthermore, advancements in HDAC research can pave the way for the development of more effectivetreatments and potentially reduce the economic burden of these diseases on individuals and societies.

Histone deacetylases are a family of enzymes that regulate gene expression and have been implicated in the development and progression of various diseases. By removing acetyl groups from histones, HDACs can alter the accessibility of DNA to transcription factors and impact gene activity. Abnormal HDAC function has been linked to cancer, neurological disorders like Alzheimer's and Parkinson's disease, and inflammatory conditions.

The thematic issue aims to gather cutting-edge research on HDACs and showcase their potential as drug targets. "Research on HDACs has the potential to uncover new therapeutic strategies for these diseases,"the announcement states. Several HDAC inhibitors have already been approved for the treatment of certain cancers, but much remains to be explored in terms of their mechanisms of action and applications in other disease areas.

Pharmaceuticals is one of MDPI's flagship journals, publishing original research articles, reviews, and short communications covering all aspects of pharmaceutical sciences. As an open-access journal, it makes all published articles immediately available worldwide, accelerating the dissemination of the latest scientific findings.

The deadline for submissions to the thematic issue on HDACs has been set, and interested researchers are encouraged to submit their papers for consideration. With the growing recognition of HDACs as key players in disease processes and potential therapeutic targets, this special issue is poised to advance our understanding of these critical enzymes and theirapplicationsin medicine.